Minaris Advanced Therapies is proud to welcome three accomplished leaders to its executive team, reflecting our commitment to support the future of cell and gene therapy. Effective May 19, 2025, Kaia Boyd joined as Chief Human Resources Officer, Rachel Collins Clarke as Chief Legal Officer and General Counsel, and Ilya Koltover as Chief Transformation Officer.
Kaia Boyd is a strategic HR leader and business partner with deep experience in contract development and manufacturing organizations (CDMOs). In her role as CHRO, Kaia is responsible for developing and executing the company’s people strategy in alignment with business goals, overseeing all aspects of the employee experience, and serving as a strategic advisor to the CEO and Board. She most recently served as Senior Director, People & Culture at Societal CDMO, prior to which she held HR leadership roles at Ajinomoto Bio-Pharma Services. Kaia is a SHRM Senior Certified Professional and holds a Bachelor of Science degree from the University of Arizona.
Rachel Collins Clarke is a senior biotechnology lawyer with experience advising commercial, clinical, and operational teams at leading cell and gene therapy companies. As Chief Legal Officer and General Counsel at Minaris Advanced Therapies, she leads the global legal function in support of the company’s role of delivering transformative cell and gene therapies on behalf of our clients worldwide. Rachel serves on the executive team, providing strategic counsel to advance Minaris’ growth, legal and governance objectives. Prior to joining Minaris, Rachel held legal leadership roles at Adaptimmune and Spark Therapeutics, was a partner at Cozen O’Connor and an associate at Morgan, Lewis & Bockius LLP. Rachel holds a Juris Doctor degree from Georgetown University Law Center and a Bachelor of Arts degree from William & Mary.
Ilya Koltover is an experienced commercial leader in the life science industry with strong strategy, operations, and technical background. In his role as Chief Transformation Officer, Ilya will lead initiatives designed to ensure business operations are aligned with the company’s strategic vision and goals. Ilya was recently Chief Commercial Officer for Solvias, and previously held leadership positions at MilliporeSigma, Merck Life Sciences, and Sigma-Aldrich. He received his Ph.D. in Physics from the University of California, Santa Barbara, and his MS in Physics from the University of Pennsylvania.
“I am delighted to welcome Kaia, Rachel, and Ilya to Minaris Advanced Therapies. Building the leading cell therapy CDMO requires leaders with knowledge of cell therapies experience in commercial manufacturing,” said Iain Baird, chairman of Minaris Advanced Therapies. “We are now only weeks away from presenting the entire leadership team.”